These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 33099859)

  • 1. Plant-made dengue virus-like particles produced by co-expression of structural and non-structural proteins induce a humoral immune response in mice.
    Ponndorf D; Meshcheriakova Y; Thuenemann EC; Dobon Alonso A; Overman R; Holton N; Dowall S; Kennedy E; Stocks M; Lomonossoff GP; Peyret H
    Plant Biotechnol J; 2021 Apr; 19(4):745-756. PubMed ID: 33099859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
    Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice.
    Arora U; Tyagi P; Swaminathan S; Khanna N
    Vaccine; 2013 Jan; 31(6):873-8. PubMed ID: 23261049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
    Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
    BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope.
    Metz SW; Thomas A; White L; Stoops M; Corten M; Hannemann H; de Silva AM
    Virol J; 2018 Apr; 15(1):60. PubMed ID: 29609659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine.
    Galula JU; Shen WF; Chuang ST; Chang GJ; Chao DY
    J Virol; 2014 Sep; 88(18):10813-30. PubMed ID: 25008922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination with dengue virus-like particles induces humoral and cellular immune responses in mice.
    Zhang S; Liang M; Gu W; Li C; Miao F; Wang X; Jin C; Zhang L; Zhang F; Zhang Q; Jiang L; Li M; Li D
    Virol J; 2011 Jun; 8():333. PubMed ID: 21714940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation and preclinical immunogenicity study of dengue type 2 virus-like particles derived from stably transfected mosquito cells.
    Suphatrakul A; Yasanga T; Keelapang P; Sriburi R; Roytrakul T; Pulmanausahakul R; Utaipat U; Kawilapan Y; Puttikhunt C; Kasinrerk W; Yoksan S; Auewarakul P; Malasit P; Charoensri N; Sittisombut N
    Vaccine; 2015 Oct; 33(42):5613-5622. PubMed ID: 26382602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies.
    Poddar A; Ramasamy V; Shukla R; Rajpoot RK; Arora U; Jain SK; Swaminathan S; Khanna N
    BMC Biotechnol; 2016 Jun; 16(1):50. PubMed ID: 27301568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of virus-neutralizing antibodies and T cell responses by dengue virus type 1 virus-like particles prepared from Pichia pastoris.
    Tang YX; Jiang LF; Zhou JM; Yin Y; Yang XM; Liu WQ; Fang DY
    Chin Med J (Engl); 2012 Jun; 125(11):1986-92. PubMed ID: 22884066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice.
    Ramasamy V; Arora U; Shukla R; Poddar A; Shanmugam RK; White LJ; Mattocks MM; Raut R; Perween A; Tyagi P; de Silva AM; Bhaumik SK; Kaja MK; Villinger F; Ahmed R; Johnston RE; Swaminathan S; Khanna N
    PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006191. PubMed ID: 29309412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tests in mice of a dengue vaccine candidate made of chimeric Junin virus-like particles and conserved dengue virus envelope sequences.
    Mareze VA; Borio CS; Bilen MF; Fleith R; Mirazo S; Mansur DS; Arbiza J; Lozano ME; Bruña-Romero O
    Appl Microbiol Biotechnol; 2016 Jan; 100(1):125-33. PubMed ID: 26386688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2.
    Arora U; Tyagi P; Swaminathan S; Khanna N
    J Nanobiotechnology; 2012 Jul; 10():30. PubMed ID: 22794664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant Dengue Virus 4 Envelope Glycoprotein Virus-Like Particles Derived from Pichia pastoris are Capable of Eliciting Homotypic Domain III-Directed Neutralizing Antibodies.
    Khetarpal N; Shukla R; Rajpoot RK; Poddar A; Pal M; Swaminathan S; Arora U; Khanna N
    Am J Trop Med Hyg; 2017 Jan; 96(1):126-134. PubMed ID: 27821688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel expression of immunogenic foot-and-mouth disease virus-like particles in Nicotiana benthamiana.
    Veerapen VP; van Zyl AR; Wigdorovitz A; Rybicki EP; Meyers AE
    Virus Res; 2018 Jan; 244():213-217. PubMed ID: 29196195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dengue-2 virus-like particle (VLP) based vaccine elicits the highest titers of neutralizing antibodies when produced at reduced temperature.
    Boigard H; Cimica V; Galarza JM
    Vaccine; 2018 Nov; 36(50):7728-7736. PubMed ID: 30377067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dimerization of Dengue Virus E Subunits Impacts Antibody Function and Domain Focus.
    Thomas A; Thiono DJ; Kudlacek ST; Forsberg J; Premkumar L; Tian S; Kuhlman B; de Silva AM; Metz SW
    J Virol; 2020 Aug; 94(18):. PubMed ID: 32611757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting of envelope domain III protein of DENV type 2 to DEC-205 receptor elicits neutralizing antibodies in mice.
    Coconi-Linares N; Ortega-Dávila E; López-González M; García-Machorro J; García-Cordero J; Steinman RM; Cedillo-Barrón L; Gómez-Lim MA
    Vaccine; 2013 May; 31(19):2366-71. PubMed ID: 23499580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and production of dengue virus chimeric proteins useful for developing tetravalent vaccines.
    Batista ICA; Quinan BR; Rocha Alves ÉA; Jangola STG; Oliveira ES; Colombarolli SG; Ferreira JGG; Rocha ESO; Kroon EG; de Assis RR; de Oliveira JG; Fiuza JA; Calzavara-Silva CE
    Vaccine; 2020 Feb; 38(8):2005-2015. PubMed ID: 31982262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pichia pastoris-expressed dengue 2 envelope forms virus-like particles without pre-membrane protein and induces high titer neutralizing antibodies.
    Mani S; Tripathi L; Raut R; Tyagi P; Arora U; Barman T; Sood R; Galav A; Wahala W; de Silva A; Swaminathan S; Khanna N
    PLoS One; 2013; 8(5):e64595. PubMed ID: 23717637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.